ERBB2 and neoplasm: On the contrary, among women with HER2-positive/hormone receptor-positive tumours, disease-free survival (adjusted HR, 0.58; 95% CI, 0.45 – 0.76) and overall survival (adjusted HR, 0.63; 95% CI, 0.40 – 0.99) were significantly better for patients who developed treatment-induced amenorrhea.